Cyclopharm Signs Five Year Collaborative Agreement with the Canadian Association of Nuclear Medicine

Australian radiopharmaceutical company Cyclopharm Limited (ASX: CYC) is pleased to announce a strategic partnership with the Canadian Association of Nuclear Medicine (CANM).

The partnership is consistent with Cyclopharm’s strategic objectives of:

1. Developing the United States market for Technegas, the company’s proprietary superior functional lung ventilation imaging agent, following anticipated USFDA approval and;
2. Expanding the use of Technegas across the company’s existing 55 established markets as well as other new markets and clinical applications to include COPD, asthma, pulmonary hypertension and lung cancer.

As part of this five year agreement, CYC will assist the CANM – through cash and in kind support – to promote state-of-the-art, appropriate and safe nuclear medicine services across Canada and to position the CANM as a major educator and contributor to the development of nuclear medicine in the rest of the world.

The CANM will work collaboratively with CYC to advocate for the use of nuclear medicine in the diagnosis and follow up of pulmonary embolism based on clinical best practices, particularly those endorsed by the European Association of Nuclear Medicine (EANM), which endorses Technegas as the best aerosol for functional lung ventilation imaging.

The CANM will also join forces with CYC to advocate for peer reviewed, validated clinical trials and evidence-based published guidelines on the use and benefits of nuclear medicine imaging in applications beyond Pulmonary Embolism such as COPD, asthma, pulmonary hypertension and lung cancer.

In line with the CANM strategic plan, the Association will collaborate with CYC in developing educational support programs that will promote clinical nuclear medicine best practice for lung ventilation/perfusion imaging across Canada and in the United States following anticipated USFDA approval for Technegas.

President of the CANM Dr Andrew Ross stated that “the Association is delighted to partner with Cyclopharm.”

“Lung imaging continues to represent a major clinical tool in the field of nuclear medicine not only for the traditional use in pulmonary embolism but also with the arrival of newer technology to be
researched and expanded into serious disease states including COPD, asthma, pulmonary hypertension and lung cancer,” Dr Ross said.

Dr Ross went on to say that “this strategic partnership with Cyclopharm is designed to promote high standards of clinical practice in the discipline of nuclear medicine to referring physicians including those in respiratory referring medicine to broaden the use of functional lung imaging globally.”

Mr McBrayer, CEO of Cyclopharm, said: “It is an honour to formally partner with the CANM. Their leadership and clinical advocacy demonstrated through education and activism in support of the practice of nuclear medicine is an example for the rest of world to follow. Given the level of passion and expertise demonstrated by its members, it is no coincidence that Canada is our largest single market for Technegas in the world.”

“CYC has been a long term supporter of the CANM. This formal agreement, representing CAD$35,000 per year over the next five years and additional in kind support over the next three years totalling CAD$150,000, will be instrumental in delivering on our strategic objectives of entering and developing the United States market following USFDA approval and expanding the clinical use of Technegas globally,” Mr McBrayer added.

For more information, please contact:

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

Ms Hélène Samson  
Executive Director/Directrice générale  
Canadian Association of Nuclear Medicine Association  
T: +1 (613) 882 5097

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700°C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Canadian Association of Nuclear Medicine

The Canadian Association of Nuclear Medicine strives for excellence in the practice of diagnostic and therapeutic nuclear medicine by promoting the continued professional competence of nuclear medicine specialists, establishing guidelines of clinical practice, and encouraging biomedical research. We work with all professionals in nuclear medicine to ensure that Canadians have access to the highest quality nuclear medicine services.